NCT00637572 - Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

HIV InfectionsCachexiaAnorexiaAIDS Wasting SyndromeHIV Wasting Syndrome

Interventions

DRUG

Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL

Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)

DRUG

Megestrol acetate oral suspension 40 mg/mL

Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)

Trial Locations (12)

40 Arthur Hobbs Street, Boksburg

St Mary's Hospital, Private Bag

6 Calypso Centre, Richards Bay

Genclin Corporation, Clinical Trial Centre, Westdene

Quinta-research, Pellissier

Drexel University College of Medicine, Philadelphia

Ruby Hall Clinic and Grant Medical Foundation, Pune

Victoria Hospital, Bangalore

M.S. Ramaiah Medical College and Hospital, Bangalore

Kasturba Medical College, Mangalore

Eastmed Hospital, Eastlynn

TrialTech Clinical Research, Hatfield